• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Vedolizumab for Crohn's disease: Real-world efficacy through a meta-analytical lens.维多珠单抗治疗克罗恩病：基于荟萃分析视角的真实世界疗效
United European Gastroenterol J. 2025 May;13(4):503-504. doi: 10.1002/ueg2.12690. Epub 2024 Nov 7.
2
A SPECIAL MEETING REVIEW EDITION: Highlights in Inflammatory Bowel Disease From the 14th Congress of ECCO: A Review of Selected Presentations From the 14th Congress of the European Crohn's and Colitis Organisation (ECCO) • March 6-9, 2019 • Copenhagen, Denmark• VARSITY: A Double-Blind, Double-Dummy, Randomized Controlled Trial of Vedolizumab Versus Adalimumab in Patients With Active Ulcerative Colitis• Analyses of Data From the VISIBLE 1 and 2 Trials: Vedolizumab in Patients With Ulcerative Colitis or Crohn's Disease• Improved Endoscopic Outcomes and Mucosal Healing of Upadacitinib as an Induction Therapy in Adults With Moderately to Severely Active Ulcerative Colitis: Data From the U-ACHIEVE Study• Long-Term Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease: Final Results From the GEMINI LTS Study• Pediatric Crohn's Disease Adalimumab Level-Based Optimization Treatment (PAILOT) Randomized Controlled Trial• Maintenance Treatment With Mirikizumab, a P19-Directed IL-23 Antibody: 52-Week Results in Patients With Moderately to Severely Active Ulcerative Colitis• Real-World Effectiveness and Safety of Vedolizumab and Anti-TNF Therapy in Biologic-Naive Patients With Ulcerative Colitis or Crohn's Disease: Results From the EVOLVE Study• A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of a Targeted-Release Oral Cyclosporine Formulation in the Treatment of Mild to Moderate Ulcerative Colitis: Efficacy Results• Real-World Analyses of Patients With IBD Treated With Vedolizumab Professor of MedicineDivision of Gastroenterology and HepatologyMayo ClinicRochester, Minnesota.特别会议回顾版：欧洲克罗恩病和结肠炎组织（ECCO）第14届大会炎症性肠病亮点：对第14届欧洲克罗恩病和结肠炎组织（ECCO）大会部分演讲的回顾 • 2019年3月6 - 9日 • 丹麦哥本哈根• VARSITY：维多珠单抗与阿达木单抗治疗活动性溃疡性结肠炎患者的双盲、双模拟、随机对照试验• 来自VISIBLE 1和2试验的数据分析：维多珠单抗治疗溃疡性结肠炎或克罗恩病患者• 乌帕替尼作为中度至重度活动性溃疡性结肠炎成人诱导治疗的内镜结果改善和黏膜愈合：U - ACHIEVE研究数据• 维多珠单抗治疗溃疡性结肠炎和克罗恩病的长期安全性：GEMINI LTS研究最终结果• 儿童克罗恩病阿达木单抗基于水平的优化治疗（PAILOT）随机对照试验• 抗P19导向的IL - 23抗体mirikizumab维持治疗：中度至重度活动性溃疡性结肠炎患者52周结果• 维多珠单抗和抗TNF治疗在初治溃疡性结肠炎或克罗恩病患者中的真实世界有效性和安全性：EVOLVE研究结果• 靶向释放口服环孢素制剂治疗轻至中度溃疡性结肠炎的随机、多中心、双盲、安慰剂对照研究：疗效结果• 接受维多珠单抗治疗的炎症性肠病患者的真实世界分析 医学教授 胃肠病学和肝病科 梅奥诊所 明尼苏达州罗切斯特
Gastroenterol Hepatol (N Y). 2019 May;15(5 Suppl 2):1-24.
3
Therapeutic sequencing in inflammatory bowel disease: Determining the optimal position of vedolizumab for long-term Crohn's disease control using real-world evidence.炎症性肠病的治疗序贯策略：利用真实世界证据确定vedolizumab 在长期克罗恩病控制中的最佳位置。
United European Gastroenterol J. 2024 Jun;12(5):574-584. doi: 10.1002/ueg2.12563. Epub 2024 May 8.
4
Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis.英夫利昔单抗与维得利珠单抗治疗炎症性肠病患者的疗效和安全性比较：系统评价和荟萃分析。
BMC Gastroenterol. 2022 Jun 8;22(1):291. doi: 10.1186/s12876-022-02347-1.
5
Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort.真实世界中 vedolizumab 治疗炎症性肠病的疗效和安全性：苏格兰 vedolizumab 队列研究。
J Crohns Colitis. 2019 Sep 19;13(9):1111-1120. doi: 10.1093/ecco-jcc/jjz042.
6
Effectiveness and Treatment Persistence of Vedolizumab Compared to Anti-Tumour Necrosis Factor-α in Patients With Crohn's Disease: A Systematic Literature Review and Meta-Analysis.维多珠单抗与抗肿瘤坏死因子-α治疗克罗恩病患者的有效性及治疗持久性：一项系统文献综述与荟萃分析
United European Gastroenterol J. 2025 May;13(4):552-565. doi: 10.1002/ueg2.12705. Epub 2024 Dec 21.
7
Real-World Outcomes of Vedolizumab Therapy in Ulcerative Colitis and Crohn's Disease at a Tertiary Referral Center.三级转诊中心维多珠单抗治疗溃疡性结肠炎和克罗恩病的真实世界疗效
Dig Dis. 2019;37(1):33-44. doi: 10.1159/000492322. Epub 2018 Aug 22.
8
Effectiveness and safety outcomes after long-term (54 weeks) vedolizumab therapy for Crohn's disease: a prospective, real-world observational study including patient-reported outcomes (POLONEZ II).维多珠单抗长期（54周）治疗克罗恩病后的有效性和安全性结果：一项前瞻性、真实世界观察性研究，纳入患者报告结局（POLONEZ II）
Therap Adv Gastroenterol. 2024 Nov 20;17:17562848241293938. doi: 10.1177/17562848241293938. eCollection 2024.
9
Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study.维多珠单抗在炎症性肠病中的真实世界疗效：瑞典前瞻性多中心SVEAH研究的第52周结果
Therap Adv Gastroenterol. 2021 Jul 3;14:17562848211023386. doi: 10.1177/17562848211023386. eCollection 2021.
10
Vedolizumab for induction and maintenance of remission in Crohn's disease.维得利珠单抗用于诱导和维持克罗恩病缓解。
Cochrane Database Syst Rev. 2023 Jul 17;7(7):CD013611. doi: 10.1002/14651858.CD013611.pub2.

本文引用的文献

1
Effectiveness and Treatment Persistence of Vedolizumab Compared to Anti-Tumour Necrosis Factor-α in Patients With Crohn's Disease: A Systematic Literature Review and Meta-Analysis.维多珠单抗与抗肿瘤坏死因子-α治疗克罗恩病患者的有效性及治疗持久性：一项系统文献综述与荟萃分析
United European Gastroenterol J. 2025 May;13(4):552-565. doi: 10.1002/ueg2.12705. Epub 2024 Dec 21.
2
Modern Advanced Therapies for Inflammatory Bowel Diseases: Practical Considerations and Positioning.炎症性肠病的现代先进疗法：实际考量与定位
Clin Gastroenterol Hepatol. 2025 Feb;23(3):454-468. doi: 10.1016/j.cgh.2024.06.050. Epub 2024 Aug 13.
3
Biologic Therapy for Inflammatory Bowel Disease: Real-World Comparative Effectiveness and Impact of Drug Sequencing in 13 222 Patients within the UK IBD BioResource.生物疗法治疗炎症性肠病：英国 IBD 生物资源库中 13222 例患者的真实世界比较有效性和药物序贯治疗的影响。
J Crohns Colitis. 2024 Jun 3;18(6):790-800. doi: 10.1093/ecco-jcc/jjad203.
4
Integrating Evidence to Guide Use of Biologics and Small Molecules for Inflammatory Bowel Diseases.整合证据以指导生物制剂和小分子药物在炎症性肠病中的应用。
Gastroenterology. 2024 Mar;166(3):396-408.e2. doi: 10.1053/j.gastro.2023.10.033. Epub 2023 Nov 8.
5
How many biomarker measurements are needed to predict prognosis in Crohn's disease patients under infliximab?-A prospective study.需要多少生物标志物测量来预测英夫利昔单抗治疗的克罗恩病患者的预后？一项前瞻性研究。
United European Gastroenterol J. 2023 Jul;11(6):531-541. doi: 10.1002/ueg2.12420. Epub 2023 Jun 15.
6
Has the therapeutical ceiling been reached in Crohn's disease randomized controlled trials? A systematic review and meta-analysis.在克罗恩病的随机对照试验中是否已经达到了治疗的上限？一项系统评价和荟萃分析。
United European Gastroenterol J. 2023 Mar;11(2):202-217. doi: 10.1002/ueg2.12366. Epub 2023 Mar 6.
7
Comparative Risk of Serious Infections With Biologic Agents and Oral Small Molecules in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.生物制剂与口服小分子药物治疗炎症性肠病严重感染风险的比较：系统评价和荟萃分析。
Clin Gastroenterol Hepatol. 2023 Apr;21(4):907-921.e2. doi: 10.1016/j.cgh.2022.07.032. Epub 2022 Aug 6.
8
Vedolizumab treatment persistence and safety in a 2-year data analysis of an extended access programme.在一项扩展准入计划的 2 年数据分析中，vedolizumab 治疗的持续性和安全性。
Aliment Pharmacol Ther. 2021 Jan;53(2):265-272. doi: 10.1111/apt.16160. Epub 2020 Nov 18.

Vedolizumab for Crohn's disease: Real-world efficacy through a meta-analytical lens.

作者信息

Estevinho Maria Manuela, Solitano Virginia

机构信息

Department of Gastroenterology, Unidade Local de Saúde Gaia Espinho (ULSGE), Vila Nova de Gaia, Portugal.

Department of Biomedicine, Unit of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Porto, Portugal.

出版信息

United European Gastroenterol J. 2025 May;13(4):503-504. doi: 10.1002/ueg2.12690. Epub 2024 Nov 7.

DOI:10.1002/ueg2.12690
PMID:39508358
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12090824/
Abstract
摘要